Fig. 1

Glycyrrhizin may improve the adverse symptoms and pathological status of IMD by inhibiting the expression of IL-17A and IFN-γ. a Compared with the control IMD mice (treated with normal saline), after continuous treatment with 20 mg/kg MTX or 20 mg/kg glycyrrhizin for 4 days, the adverse symptoms of IMD were substantially improved by MTX or glycyrrhizin. b The HE staining experiments show that MTX or glycyrrhizin substantially improved the pathological status of the skin cells in IMD. c By the ELISA experiments, we found that the pro-inflammatory cytokines IL-17A and INF-γ were substantially inhibited by MTX or glycyrrhizin in the serum of IMD. NOTES: Data are presented as the mean ± SD (n = 3). ***P < 0.001; GA represents glycyrrhizin; IL-17 represents IL-17A; Model represents IMD mice